Diagnostic and assessment issues related to pharmacotherapy for children and adolescents with autism.
Autism involves not only developmental delays but also aberrant behavior, both of which change in nature over time. Rating instruments may be useful to assess maladaptive and adaptive behaviors of autistic children in a standardized way and, perhaps, to measure change due to treatment. With the expansion of basic science, knowledge, and technology, there is increasing evidence that autism is etiologically heterogeneous. Currently, there is no biological marker specific to autism, although hyperserotonemia is a consistent finding in one third of autistic children. An aim of basic science research has been to develop a rational pharmacotherapy based upon the underlying neurochemistry. However, at the present time, this approach has not always been successful. It is expected that the development and use of more restrictive criteria, delineation of subtypes of autism, and interaction of descriptive, behavioral, clinical, and basic research will lead to more effective planning for treatment. The relationship of assessment to treatment response is presented and discussed.
Campbell
M
M
Department of Psychiatry, New York University Medical Center, NY 10016.
Kafantaris
V
V
Malone
R P
RP
Kowalik
S C
SC
Locascio
J J
JJ
D000293:Adolescent; D001321:Autistic Disorder / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy* / Q000523:psychology; D002648:Child; D003131:Combined Modality Therapy; D006801:Humans; D009483:Neuropsychological Tests; D010552:Personality Assessment